Kentucky Pharmacology of Medical Cannabis

Course Overview

Course Outline

1. Introduction 
2. Kentucky Prescribing Law  
3. Overview and Definition 
4. Clinical Application and Use 
5. Pharmacokinetics  
   1. Definition 
   2. Drug Class 
   3. Uses 
   4. Mechanism of Action 
   5. Side effects 
   6. Warnings 
   7. Alternatives 
6. Cannabis Use Disorder 
7. Nursing Considerations / Follow Up 
8. Upcoming Research and Legislation 
9. Conclusion

Accreditation Statement

Nursing CE Central LLC is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

In this course, we will discuss Kentucky Pharmacology of Medical Cannabis. It will take the average learner 180 minutes to complete and awards 3 pharmacology contact hours of continuing education.

Course Outcomes

After completing this course, the learner will rate a 4 out of 5 on the Likert Scale for their ability to:

1. Identify the prescribing laws and regulations of medical cannabis at both the federal and state levels, with a focus on regulations in the state of Kentucky.
2. Explain the basic pharmacology of cannabis and its interaction with the endocannabinoid system (ECS).
3. Differentiate between the effects of THC and CBD on the human body.
4. Evaluate the therapeutic uses of medical cannabis for conditions such as chronic pain, epilepsy, multiple sclerosis, and PTSD.
5. Develop treatment plans incorporating medical cannabis, considering factors such as dosage, method of administration, and patient-specific conditions.

Target Audience

• Registered Nurses (RN)
• Advanced Practice Registered Nurses (APRN)
• Licensed Practical Nurses (LPN/LVN)

Requirement for Completion

1. Enrollment in the course by the learner
2. Read and learn all course materials
3. Complete the course evaluation
4. Attest and testify learning of the course materials

Accreditations + Approvals

Disclosure of Relevant Financial Relationships

Nursing CE Central nor any of the authors, planners, content experts, or any contributors have any relevant financial relationships with ineligible companies to disclose.